Why Employers Need a Prescription Drug Strategy Built for Uncertainty
By
Employers are being asked to budget for a category in which neither the timing nor the magnitude of the next major expense is completely predictable.
That uncertainty comes from two directions.
First, there is clinical uncertainty. A single member may need a specialty medication costing hundreds of thousands of dollars annually, creating a significant and potentially recurring financial obligation.
Then there is market uncertainty. Even when competition is expected to reduce the cost of an expensive drug, employers cannot be certain when that competition will reach the market or how much cost reduction their plan will actually experience.
Together, these challenges make one thing clear: employers cannot predict every high-cost prescription or market shift. But they can build a strategy designed to respond to them.

1. Know Where Your Exposure Actually Lives
High-cost therapies do not always appear within the pharmacy benefit. Infusions and other specialty treatments may run through the medical benefit, making it important to evaluate both when assessing total exposure.
Employers need visibility into the therapies, sourcing arrangements, and benefit structures driving their costs.
2. Separate Predictable Costs From Unpredictable Risk
An ongoing specialty medication creates a different financial challenge than a one-time cell or gene therapy.
Scenario planning can help employers distinguish recurring obligations from high-impact, less predictable claims and understand how each could affect the plan.
The question isn’t simply, “What will this cost?” It’s “How prepared is our plan to absorb the financial impact?”
3. Don’t Budget for Cost Reductions That Haven’t Arrived Yet
Patent expiration does not necessarily mean immediate competition or lower costs.
Biosimilars may take time to reach the market, and PBM contracts, formulary decisions, and rebate structures can influence whether competition ultimately reduces the employer’s cost.
Employers should monitor market changes without building anticipated cost reductions into their strategy before there is a clear path to realizing them.

4. Know What “Net Cost” Actually Means for Your Plan
A larger rebate or discount does not automatically make a drug the lowest-cost option.
Employers should evaluate acquisition costs, rebates, formulary placement, sourcing, and plan design together to understand what the plan is actually paying.
The goal should be to pursue the lowest appropriate net cost while maintaining access to the medications members need.
5. Build the Response Mechanism Before You Need It
By the time an employer discovers a high-cost prescription, treatment may already be underway, and options may be more limited.
A stronger strategy establishes the response before the claim occurs: how high-cost prescriptions are identified, who evaluates sourcing and coverage options, how medical and pharmacy claims are reviewed, and how emerging lower-cost alternatives are considered.
That preparation allows employers to respond deliberately instead of reacting after the financial impact has already reached the plan.

Prepare for What You Can’t Predict
No employer can know which member will need the next breakthrough therapy or exactly when new competition will change the economics of an expensive drug.
But employers can control how prepared they are.
They can improve visibility, understand their exposure, evaluate true net cost, and establish a cost-containment strategy before the next high-cost prescription arrives.
That balance is central to SHARx’s approach: Compassionate Care. Powerful Procurement. Members need access to therapies that can transform their lives, while employers need a sustainable way to manage the financial impact of providing that access.
The goal isn’t to predict the next expensive prescription. It’s to build a benefits strategy that isn’t thrown off course when it arrives.
